Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
12.58
+0.15 (1.21%)
At close: Dec 5, 2025, 4:00 PM EST
14.00
+1.42 (11.29%)
After-hours: Dec 5, 2025, 7:59 PM EST
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 22.33, with a low estimate of 17 and a high estimate of 31. The average target predicts an increase of 77.50% from the current stock price of 12.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ocular Therapeutix stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 3 | 4 | 4 |
| Buy | 7 | 7 | 5 | 4 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 7 | 7 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +51.03% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +66.93% | Nov 5, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $14 → $20 | Strong Buy | Maintains | $14 → $20 | +58.98% | Oct 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $19 | Strong Buy | Maintains | $15 → $19 | +51.03% | Oct 8, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $21 → $31 | Buy | Maintains | $21 → $31 | +146.42% | Oct 3, 2025 |
Financial Forecast
Revenue This Year
56.04M
from 63.72M
Decreased by -12.06%
Revenue Next Year
64.38M
from 56.04M
Increased by 14.88%
EPS This Year
-1.49
from -1.22
EPS Next Year
-1.40
from -1.49
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 71.2M | 87.0M | ||||
| Avg | 56.0M | 64.4M | ||||
| Low | 49.3M | 51.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.7% | 55.3% | ||||
| Avg | -12.1% | 14.9% | ||||
| Low | -22.6% | -8.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.50 | -1.12 | ||||
| Avg | -1.49 | -1.40 | ||||
| Low | -1.47 | -1.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.